Autonomic Testing in Functional Gastrointestinal Disorders: Implications of Reproducible Gastrointestinal Complaints during Tilt Table Testing

Table 3

Treatment choices in both groups.

Treatment group	Overall	RGI 𝑛=32	NRGI 𝑛=44
Volume expansion/ Fludrocortisone	23/76 (30%)	15/32 (47%)	8/44 (18%)
Tricyclic antidepressant	9/76 (12%)	6/32 (19%)	3/44 (7%)
Beta-blockers	25/76 (32%)	10/32 (31%)	15/44 (34%)
Cyproheptadine	3/76 (4%)	2/32 (6%)	1/44 (2%)
SSRI’s	18/76 (23%)	10/32 (31%)	8/44 (18%)
Antiepileptic	5/76 (6%)	2/32 (6%)	3/44 (7%)
Proamatine	9/76 (12%)	5/32 (16%)	4/44 (9%)
Neurontin	2/76 (2%)	1/32 (3%)	1/44 (2%)
Mestinon	1/76 (1%)	1/32 (3%)	0/44 (0%)
No Treatment	17/76 (22%)	3/32 (9%)	14/44 (31%)